Skip to content
naulon

Not checkedNot checked for notices yet.

Genetic dissection of down syndrome-associated alterations in APP/amyloid-β biology using mouse models

Justin L. Tosh, Elena R. Rhymes, Paige Mumford and 10 more

Scientific Reports · 2021

doi:10.1038/s41598-021-85062-3 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Individuals who have Down syndrome (caused by trisomy of chromosome 21), have a greatly elevated risk of early-onset Alzheimer’s disease, in which amyloid-β accumulates in the brain. Amyloid-β is a product of the chromosome 21 gene APP (amyloid precursor protein) and the extra copy or ‘dose’ of APP is thought to be the cause of this early-onset Alzheimer’s disease. However, other chromosome 21 genes likely modulate disease when in three-copies in people with Down syndrome. Here we show that an extra copy of chromosome 21 genes, other than APP , influences APP/Aβ biology. We crossed Down syndrome mouse models with partial trisomies, to an APP transgenic model and found that extra copies of subgroups of chromosome 21 gene(s) modulate amyloid-β aggregation and APP transgene-associated mortality, independently of changing amyloid precursor protein abundance. Thus, genes on chromosome 21, other than APP, likely modulate Alzheimer’s disease in people who have Down syndrome.

Abstract licence: CC BY-NC-ND

References36

  1. 10.
  2. 12.
  3. 21.
  4. 26.
  5. 27.
  6. 29.

30 more references, whose wording the paper’s licence keeps private.

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.